@article{fef42d5502e9460493eaf9a0aef689cf,
title = "A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study",
abstract = "Objectives. The Gynecologic Oncology Group (GOG) performed a randomized phase II study to determine the antitumor activity and toxicity of two different schedules of bryostatin-1 administration in patients with recurrent or persistent platinum-sensitive epithelial ovarian cancer or primary peritoneal carcinoma. Methods. Eligible patients were randomized to receive either bryostatin-1 25 μg/m2 as a 1 h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I) or bryostatin-1 120 μg/m2 as a 72 h continuous infusion every 2 weeks (Regimen II). Results. Fifty-five patients were enrolled on this study. There was one durable response among 27 eligible patients (response rate = 3.7%) on Regimen II and no responses in the 27 eligible patients on Regimen I. Nineteen patients (eleven on Regimen I and eight on Regimen II) had stable disease. The most common adverse event was myalgia, with 12 of 27 patients (44%) on each regimen experiencing some degree of myalgia. There were no other significant toxicities on either treatment arm. Conclusions. Both of these schedules and doses of bryostatin-1 are inactive as single agents in previously treated epithelial ovarian cancer.",
keywords = "Bryostatin-1, Ovarian cancer, Platinum-sensitive, Protein kinase C (PKC)",
author = "Armstrong, {Deborah K.} and Blessing, {John A.} and Look, {Katherine Y.} and Russell Schilder and Nunez, {Evelyn R.}",
note = "Funding Information: This study was supported by National Cancer Institute grants to the GOG Administrative Office (CA 27469) and the GOG Statistical and Data Center (CA 37517). The following member institutions participated in this study: University of Alabama at Birmingham, Duke University Medical Center, Abington Memorial Hospital, Emory University Clinic, University of Mississippi Medical Center, University of Pennsylvania Cancer Center, Milton S. Hershey Medical Center, Georgetown University Hospital, University of North Carolina Medical Center, University of Iowa Hospitals and Clinics, Indiana University Medical Center, Albany Medical College, University of California Medical Center at Irvine, Tufts-New England Medical Center, University of Illinois Cancer Center, University of Kentucky, Community Clinical Oncology Program, State University of New York at Stony Brook, Eastern Pennsylvania GYN/ ONC Center, P.C., Cooper Hospital/University Medical Center, Columbus Cancer Council, University of Massachusetts Medical Center, Fox Chase Cancer Center, Women's Cancer Center, University of Virginia, Thomas Jefferson University Hospital, Tampa Bay Cancer Consortium, Brookview Research, Inc., Ellis Fischel Cancer Center.",
year = "2003",
month = aug,
doi = "10.1023/A:1025490818450",
language = "English (US)",
volume = "21",
pages = "373--377",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",
}